To Download a copy of the presentation click here.
To Download a copy of the Q&A Responses and important links click here.
To Download a copy of the AAP weekly data report click here.
AAP Covid-19 Interim Guidance.
*This call was funded by a cooperative agreement with the Centers for Disease Control and Prevention (grant number 6 NU50CK000477-04-01). The Centers for Disease Control and Prevention is an agency within the Department of Health and Human Services (HHS). The contents of this call does not necessarily represent the policy of CDC or HHS, and should not be considered an endorsement by the Federal Government.
These one-hour webinars, held Saturdays at 3 p.m. ET, focus on timely issues of relevance to clinicians and feature case presentations by experts in the field, synthesis of new data, and an opportunity to engage with colleagues. Register for next week here.
Topic: Update on COVID-19 in the Pediatric Population
Hosted in partnership with the American Academy of Pediatrics
Moderator:
Dana S. Wollins, DrPH, MGC
Vice President, Clinical Affairs & Practice Guidelines, IDSA
Update on SARS-CoV-2 Epidemiology and Transmission in Children:
Hannah L. Kirking, MD
Epidemic Intelligence Service Officer
Division of Viral Diseases
Centers for Disease Control and Prevention
Hospital Capacity Update:
Mark Wietecha
Chief Executive Officer
Children’s Hospital Association
Emergency Department Visits and Hospital Admissions
For COVID-19 Illness in Children and Adolescents:
David Siegel, MD, MPH
LCDR U.S. Public Health Service
Medical Officer, Division of Cancer Prevention and Control
Centers for Disease Control and Prevention
Elliot Raizes, MD
Lead, Health Services and Worker Safety Task Force
COVID-19 Response
Centers for Disease Control and Prevention
COVID-19 in Children and a Safe Return to School:
Lee Ann Savio Beers, MD, FAAP
President, American Academy of Pediatrics
Professor of Pediatrics and Medical Director for Community Health and Advocacy
Children’s National Hospital
Update on Vaccine Trials for Children under 12:
Peter Marks, MD, PhD
Director
Center for Biologics Evaluation and Research
U.S. Food and Drug Administration
